Though the development of oral insulin was in the news for the last few decades, the company has now taken a major step in this regard and tied up with Nobex Corporation, USA, Ajay Bhardwaj, president (marketing), Biocon, said on Wednesday.
On the delay in developing oral insulin, despite advancement in technology, Bhardwaj said the company was working on the process, a "very delicate technology, since the insulin had to reach the right side of the body, unlike the injection."
Bhardwaj, who was in Coimbatore in connection with the launch of Biocon's first recombinant human insulin 'Insugen' in the Tamil Nadu market, said that India was expected to become the diabetic capital of the world in the coming few years.